Medical device company Artivion (NYSE: AORT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 17.5% year on year to $116.3 million. On the other hand, the company’s full-year revenue guidance of $488 million at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 35.1% below analysts’ consensus estimates.

Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Artivion’s first quarter results for 2026 were met with a significant negative market reaction, with investors responding to shortfalls in adjusted profitability and a guidance revision for the year. Management attributed these results to lower-than-expected stent graft sales, particularly in international markets and the U.S., as well as delays in AMDS starter set sales due to hospital procurement hurdles. CEO Pat Mackin acknowledged, “There were two things that did not go as planned in the first quarter,” specifically highlighting international stent softness and challenges with AMDS starter set adoption.

Looking forward, Artivion’s outlook reflects both optimism around new product launches and caution regarding execution risks. Management’s updated guidance is shaped by expectations for regulatory milestones—such as the anticipated PMA approval for AMDS and the closing of the Endospan acquisition—as well as a slower ramp-up in international stent graft sales. COO and CFO Lance Berry emphasized, “We think this is prudent guidance given the trends we have right now,” underscoring that the guidance revision incorporates ongoing market softness and internal supply chain challenges.

Key Insights from Management’s Remarks

Management emphasized that Q1 performance was driven by mixed progress across its portfolio and the impact of external market and internal operational factors.

• Stent graft challenges: International stent graft sales were lower than expected, with management citing both supply chain disruptions and weaker demand in the Middle East. The company expects these issues to be temporary but has factored ongoing softness into its updated full-year outlook.
• AMDS adoption barriers: The launch of AMDS in the U.S. faced hurdles, notably hospitals' reluctance to purchase costly starter sets ahead of PMA approval and the need for institutional review board (IRB) processes. Management is working on programs to reduce the upfront cost barrier and anticipates that regulatory approval will accelerate adoption.
• Reordering momentum: Despite slower new account additions for AMDS, reordering activity from existing accounts exceeded expectations. Management views this as a key indicator of sustained clinical adoption and long-term growth potential within established sites.
• On-X valve gains: The On-X mechanical heart valve segment continued to gain market share, particularly among patients under 65, fueled by new clinical data highlighting benefits over bioprosthetic alternatives. Management is focusing on educating providers about these advantages to drive further adoption.
• NEXUS acquisition and pipeline: The company announced its intention to acquire Endospan following FDA approval of the NEXUS aortic arch stent graft system. NEXUS is expected to complete Artivion’s aortic arch portfolio, with management highlighting its platform potential and plans for incremental PMA programs that could extend the company’s market leadership.

Drivers of Future Performance

Artivion’s guidance for the remainder of 2026 is shaped by near-term headwinds in stent graft sales, strategic investments in new product launches, and the expected approval and commercialization of key technologies.

• PMA approval for AMDS: Management expects that regulatory approval will remove administrative barriers for hospital adoption, leading to a reacceleration in AMDS starter set sales. However, guidance assumes only gradual improvement as many hospitals defer purchases until approval is secured.
• NEXUS integration and launch: The planned acquisition of Endospan and subsequent U.S. launch of the NEXUS system in early 2027 require upfront investments in inventory, specialized sales teams, and surgeon training. Management projects that these costs will weigh on EBITDA in 2026 but anticipates that U.S. NEXUS revenue will offset expenses and reach EBITDA neutrality in 2027.
• International and supply chain risks: Artivion’s outlook reflects continued caution around international stent graft demand and ongoing supply chain constraints impacting select products. Management believes these issues are specific and temporary but has built conservative assumptions into full-year expectations to account for potential delays in resolution.

Catalysts in Upcoming Quarters

In the coming quarters, our team will be monitoring (1) the timing and commercial impact of AMDS’s PMA approval, (2) progress toward closing and integrating the Endospan acquisition, and (3) evidence of stabilization or improvement in international stent graft sales and supply chain resolution. The pace of clinical trial enrollment and updates on key product launches will also be important indicators.

Artivion currently trades at $30.50, down from $35.39 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.